Moses Musonga never thought men could get breast cancer until he was diagnosed with the disease in 2013.
The 67-year-old Kenyan told the BBC that he was profoundly shock when doctors told him in 2013 that he had stage-three breast cancer, turning his life upside down.
“I was in denial and wondered why such a disease, which is not male-oriented, had singled me out of millions of men in the world,” Mr Musonga said.
Evgen Pharma (LON:EVG) is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
